LND101

Developed for: melanoma
Investigated by: Canadian Cancer Society (CCS) · Canadian Cancer Trials Group · Canadian Institutes of Health Research (CIHR) · Weston Family Foundation

today NCT06623461 · Ph 2

2026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT06623461	Apr 2025 → Dec 2028 expected	melanoma	Canadian Cancer Trials Group	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	LND101	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06623461 ↗
Route	Oral	“taken by mouth” NCT06623461 ↗